Form 4: Trevi Therapeutics Executive Simon Farrell Exercises Options and Sells Shares

Trevi Therapeutics' Chief Commercial Officer, Simon Farrell, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On March 10, 2025, Simon Farrell, Chief Commercial Officer of Trevi Therapeutics, exercised stock options to acquire common stock at prices of $0.511, $3.21, and $3.91.
• Farrell also sold shares of common stock at a weighted average price of $6.7276 and $7.1498.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on April 9, 2024.
• Following these transactions, Farrell directly owns 76,900 shares of common stock.
• A performance-based stock option for 38,400 shares vested due to the successful results of the RIVER trial.
• Farrell continues to hold options for additional shares that may vest upon the successful results of the CORAL trial.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of performance-based options is a positive sign, but the sale of shares could raise concerns, although it's under a pre-arranged plan.

Positives

• The vesting of performance-based stock options indicates the achievement of certain performance criteria related to the RIVER trial, suggesting positive progress for Trevi Therapeutics.
• The continued eligibility for vesting of additional shares based on the CORAL trial results presents further potential upside.

Negatives

• The sale of shares by a company executive could be interpreted negatively by some investors, although it was conducted under a pre-arranged trading plan.

Risks

• The vesting of additional performance-based stock options is contingent on the successful results of the CORAL trial, which introduces uncertainty.
• Market reaction to the executive's stock sales could negatively impact the share price.

Future Outlook

The document indicates that additional shares may vest based on the successful results of the CORAL trial, suggesting potential future milestones for the company.

Industry Context

This filing reflects routine insider trading activity under a pre-arranged plan, which is common in the pharmaceutical industry. The vesting of performance-based options highlights the importance of clinical trial success in incentivizing and rewarding company executives.

Comparison to Industry Standards

• Executive compensation packages including stock options and performance-based vesting are standard practice in the pharmaceutical industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize similar compensation structures to align executive incentives with company performance.
• The use of Rule 10b5-1 trading plans is a common method for executives to manage their stock holdings while avoiding accusations of insider trading.

Stakeholder Impact

• Shareholders may be interested in the executive's trading activity and the performance metrics achieved.
• Employees may view the vesting of performance-based options as a positive sign for the company's progress.

Next Steps

• Potential vesting of additional shares based on the results of the CORAL trial.
• Continued monitoring of insider trading activity.

Key Dates